Brief: Aptinyx reports results from Phase 2B study of NYX-2925 in Fibromyalgia

Aptinyx

12/08/2022 12:17

Aug 12 (Reuters) - Aptinyx Inc  APTX.O :
    * APTINYX REPORTS RESULTS FROM PHASE 2B STUDY OF NYX-2925 IN
FIBROMYALGIA
    * APTINYX INC - NYX-2925 DID NOT ACHIEVE PRIMARY ENDPOINT OF
STUDY
    * APTINYX INC - STATISTICALLY SIGNIFICANT SEPARATION FROM
PLACEBO
WAS NOT OBSERVED ON PRIMARY ENDPOINT OF STUDY WITH EITHER DOSE
LEVEL OF NYX-2925
    * APTINYX INC - ACROSS BOTH DOSE LEVELS, NYX-2925 WAS WELL
TOLERATED IN STUDY, WITH NO CONCERNING SAFETY ISSUES OBSERVED
    * APTINYX INC - WILL FOCUS OUR RESOURCES ON SUPPORTING
ADDITIONAL
READOUTS FROM OUR PIPELINE IN PTSD AND COGNITIVE IMPAIRMENT
    * APTINYX INC - DETAILED DATA FROM STUDY CONTINUE TO BE
EVALUATED

Source text for Eikon:  ID:nBw4htMcja 
Further company coverage:  APTX.O